The oncogene product MDM2 can be phosphorylated by protein kinase CK2 in vitro 0.5 ± 1 mol of phosphate were incorporated per mol MDM2 protein. The catalytic subunit of protein kinase CK2 (a-subunit) catalyzed the incorporation of twice as much phosphate into the MDM2 protein as it was obtained with the holoenzyme. Polylysine stimulated MDM2 phosphorylation by CK2 holoenzyme threefold in contrast to the a-subunitcatalyzed MDM2 phosphorylation which was reduced by about 66% when polylysine was added. Full length p53, but also a peptide representing a C-terminal fragment of the tumor suppressor gene product p53 (amino acids 264 ± 393 which also harbors the CK2b interaction site at amino acids 287 ± 340) mimicked the polylysine eect in all respects, ie. stimulation of phosphate incorporation by CK2 holoenzyme and inhibition in the presence of the catalytic CK2 a-subunit. Stimulation by p53 264 ± 393 was on the average close to twofold and inhibition in the case of the a-subunitcatalyzed MDM2 phosphorylation was about 40%. Phosphorylation of MDM2 by CK2 holoenzyme in the presence of the p21
The oncogene product MDM2 can be phosphorylated by protein kinase CK2 in vitro 0.5 ± 1 mol of phosphate were incorporated per mol MDM2 protein. The catalytic subunit of protein kinase CK2 (a-subunit) catalyzed the incorporation of twice as much phosphate into the MDM2 protein as it was obtained with the holoenzyme. Polylysine stimulated MDM2 phosphorylation by CK2 holoenzyme threefold in contrast to the a-subunitcatalyzed MDM2 phosphorylation which was reduced by about 66% when polylysine was added. Full length p53, but also a peptide representing a C-terminal fragment of the tumor suppressor gene product p53 (amino acids 264 ± 393 which also harbors the CK2b interaction site at amino acids 287 ± 340) mimicked the polylysine eect in all respects, ie. stimulation of phosphate incorporation by CK2 holoenzyme and inhibition in the presence of the catalytic CK2 a-subunit. Stimulation by p53 264 ± 393 was on the average close to twofold and inhibition in the case of the a-subunitcatalyzed MDM2 phosphorylation was about 40%. Phosphorylation of MDM2 by CK2 holoenzyme in the presence of the p21 WAF1/CIP1 , known to be a potent inhibitor of cyclin-dependent protein kinases, also led to a signi®cant reduction of phosphate incorporation into MDM2 indicating that p21 WAF1/CIP1 does not exclusively inhibit cell cycle kinases. Furthermore, these data add new insight into the autoregulatory loop which include p21 WAF1/CIP1 Introduction The mdm2 gene was originally identi®ed as a highly ampli®ed gene present on double minutes in a spontaneously transformed tumorigenic derivative of a Balb/c cell line called 3T3DM (Cahilly-Snyder et al., 1987) . Overexpression of the mdm2 gene in BALB/c 3T3 cells confers tumorigenicity in nude mice (Fakharzadeh et al., 1991) . Later also the corresponding human mdm2 gene was identi®ed (Oliner et al., 1992) . The mdm2 gene encodes a 490 amino acid protein which binds to the p53 protein and is thought to function as a regulator of p53. The MDM2 protein binds to a region in the N-terminus of p53 representing the transcription activation domain of p53 Oliner et al., 1992) . Overexpression of MDM2 protein inhibits both the transcriptional activation and the repression activities of p53 (Chen et al., 1995; Momand et al., 1992) . Thus overexpression of MDM2 protein results in a similar eect to mutational inactivation of p53. p53 can induce the expression of mdm2 gene via p53 binding site in the promoter of the mdm2 gene, suggesting an autoregulatory feed back loop in p53 regulation (Picksley and Lane, 1993; Wu et al., 1993) . The argument that MDM2 plays a critical role in regulating p53 is strengthened by the overexpression of the MDM2 protein in human sarcomas and other tumor types. The ampli®cation of MDM2 occurred only in the absence of p53 mutation supporting the idea that ampli®cation and p53 mutation are alternative mechanisms of p53 dysfunction (Reifenberger et al., 1993; Leach et al., 1993) . However, Cordon-Cardo et al. (1994) could show that ampli®cation of MDM2 can also occur in the presence of p53 mutations, although less frequently.
Protein kinase CK2 is a pleiotropic serine/threonine kinase which has been shown to phosphorylate numerous substrates. Its ubiquity in eukaryotes and the very high conservation of its amino acid composition from yeast to man strongly suggests a vital role in cellular metabolism (for reviews: see Pinna, 1990; Tuazon and Traugh, 1991; Issinger, 1993; Allende and Allende, 1995) . The enzyme has been shown to be elevated in rapidly growing cells (for review see: Issinger and Boldyre, 1992) . Among the many CK2 phosphosubstrates, the tumor suppressor gene product p53 was identi®ed (Meek et al., 1990; Herrmann et al., 1991) . In addition it was shown that CK2 and p53 associate in a molecular complex (Filhol et al., 1992; Kraiss et al., 1990; Herrmann et al., 1991; Wagner et al., 1994) .
Subsequently it was shown that the b-subunit of CK2 binds to a C-terminal domain of p53 (Appel et al., 1995) and that p21 WAF1/CIP1 interacts with protein kinase CK2 down regulating CK2 activity with respect to the phosphorylation of its regulatory b-subunit, casein and the C-terminus of p53 (GoÈ tz et al., 1996) .
Hence, there are at least ®ve major observations prompting the experiments conducted in this study: (i) CK2 preferably phosphorylates proteins with a consensus sequence S/TXXD/E, which is present to a large extent in the MDM2 protein; (ii) CK2 interacts with p53 (Filhol et al., 1992; Herrmann et al., 1991) ; (iii) oncogene product MDM2 interacts with tumor suppressor gene product p53 (Picksley and Lane, 1993; Oliner et al., 1993) . (iv) p21 WAF1/CIP1 interaction with CK2b abrogates phosphorylation of p53 (GoÈ tz et al., 1996) and (v) protein kinase CK2 holoenzyme has been shown to be stimulated by polyamines such as polylysine (Meggio et al., 1992) . Polylysine abrogates the negative regulatory eect for certain CK2 substrates such as calmodulin. From the amino acid sequence it was deduced that MDM2 protein has 20 potential CK2 phosphorylation sites and therefore we wanted to answer the question whether MDM2 protein was also a substrate for CK2 and furthermore would it behave as most of the known CK2 substrates or would it be more of a calmodulin-type substrate. Initially full length p53 was used but could be replaced by a carboxy-terminal fragment of p53 to study its eect on the phosphorylation of MDM2 protein by CK2. This proved to be more convenient without questioning the results obtained with full length p53 because: Firstly the carboxy terminus of p53 264 ± 393 contains the interaction site with the regulatory b-subunit of CK2, (ii) it contains the CK2 phosphorylation site S 392 and (iii) the C-terminal sequence harbors a high percentage of basic residues which appear partially in clusters, and thus could possibly mimick a polylysine eect.
Results

Phosphorylation of MDM2 by protein kinase CK2 holoenzyme
It is known that MDM2 protein interacts with p53 . p53 interacts with the b-subunit of protein kinase CK2 (Appel et al., 1995) and furthermore is phosphorylated by it at serine residue 392 (Meek et al., 1990) . In order to see whether MDM2 could be a suitable substrate for CK2 we analyzed the in vitro phosphorylation of MDM2 by protein kinase CK2 in the presence of [g- ]ATP does not lead to any phosphorylation indicating that no contaminating protein kinase activity was present in our MDM2 preparation. In the presence of the CK2 holoenzyme, MDM2 was strongly phosphorylated (lane d) in addition to the auto-phosphorylation of the CK2b-subunit. Incorporation of phosphate into MDM2 protein varied between 0.5 ± 1 mol/mol at 378C in 30 min.
Next we wanted to see whether addition of polylysine would lead to a stimulatory eect (Meggio et al., 1987) . For a control, protein kinase CK2 holoenzyme was incubated in the presence of polylysine. Again, as already well known (Boldyre et al., 1994) we observed autophosphorylation of the catalytic CK2a-subunit (lane e). Addition of polylysine to the CK2 holoenzyme and MDM2 protein led to a 2.5 ± 3-fold stimulation of MDM2 phosphate incorporation (lane f). From these results we conclude that MDM2 is another CK2 substrate ie. it was phosphorylated by protein kinase CK2 in the absence of polylysine, polylysine only enhanced the phosphorylation whereas heparin inhibited MDM2 phosphorylation (results not shown).
Phosphorylation of MDM2 using CK2a
In order to investigate the behaviour on MDM2 phosphorylation of CK2a-subunit we carried out a phosphorylation experiment incubating the oncoprotein in the presence of the catalytic subunit of CK2 and [g- Protein kinase CK2 is known to bind to the tumor suppressor protein p53 (Wagner et al., 1994) and the binding domain on the polypeptide chain of p53 is situated between amino acids 287 ± 340 (Appel et al., 1995) . The carboxy terminus of p53 contains a high percentage of basic residues which may mimick a possible polylysine-like eect on MDM2 phosphorylation by protein kinase CK2. Therefore we analyzed the in vitro phosphorylation of MDM2 by protein kinases CK2 holoenzyme and CK2a-subunit in the absence and presence of a C-terminal fragment of p53: CT 264 ± 393 ( Figure 3 ). All c.p.m. values counted by the Instant Imager (Packard) were normalized and expressed as percentages using the corresponding values obtained for CK2 holoenzyme and CK2a-subunit alone as 100%. When p53 264 ± 393 was added the CK2 holoenzyme-catalyzed MDM2 phosphorylation increased between 1.4 ± 3.7-fold (a paired t-test revealed a twotailed P value of 0.0251) which shows that the observed dierences are signi®cant. We have measured the in¯uence of dierent p53 264 ± 393 concentrations on MDM2 phosphorylation. Saturation was reached at 500 ng. In the presence of CK2a-subunit-catalyzed MDM2 phosphorylation we observed a 39% reduction (a similar two-tailed P value ie. 0.024, was also obtained here) when comparing the reduction of MDM2 phosphorylation in the presence of the p53 peptide compared to its absence. Initial experiments using full length p53 also stimulated phosphorylation of MDM2 by CK2 holoenzyme and also led to a comparable reduction in MDM2 phosphorylation when the catalytic subunit was used (results not shown). When an N-terminal fragment of p53 was used, comprising amino acids 1 ± 287 (lacking the CK2b binding site) and which also is not phosphorylated by the CK2 holoenzyme no stimulation of CK2-catalyzed MDM2 was observed (results not shown).
When casein or the synthetic peptide were used as substrates for CK2 holoenzyme or CK2a-subunit no signi®cant stimulatory or inhibitory eect of the p53 peptide was observed (results not shown).
Abrogation of MDM2 protein phosphorylation by CK2 in the presence of p21
Recently a new binding partner for the regulatory bsubunit of CK2 (GoÈ tz et al., 1996) was found, namely p21
. This protein is a potent inhibitor of cyclindependent kinases and is transactivated in a p53-dependent manner (El Deiry et al., 1993 . Bearing in mind the down regulatory eect of p21 WAF1/CIP1 on protein kinase CK2 activity with respect to the autophosphorylation and phosphorylation of p53 C-terminus we wanted to analyse a possible eect of p21 WAF1/CIP1 on phosphorylation of MDM2 in the presence of protein kinase CK2. In Figure 4 , lanes a and c represent controls, respectively, ie. phosphorylation of MDM2 by CK2 holoenzyme and CK2 autophosphorylation. Lane b shows the eect of p21 WAF1/CIP1 on MDM2 phosphorylation by CK2 holoenzyme.
It can be clearly seen that in the presence of p21 WAF1/ CIP1 , the phosphorylation of MDM2 protein is reduced indicating that the p21
protein exerts an inhibitory eect on protein kinase CK2 with respect to various in vitro and in vivo substrates. . Lane c autophosphorylation of CK2 Figure 3 Phosphorylation of MDM2 by CK2 holoenzyme and the a-subunit, in the presence of p53 264 ± 393 . Bar graph showing the in¯uence of the p53 fragment on MDM2 phosphorylation by CK2 holoenzyme and CK2a. The radioactivity incorporated into MDM2 protein in the absence of p53 peptide was set 100%. The obtained incorporation of radioactivity after the addition of p53 fragment either in the presence of CK2 holoenzyme or CK2a was calculated and then expressed as percent in relation to the 100% value. The values expressing the in¯uence of the p53 peptide on CK2 holoenzyme catalyzed MDM2 phosphorylation are the mean of four independent experiments MDM2 phosphorylation by CK2 B Guerra et al
Discussion
The tumor suppressor gene product p53 has drawn considerable attention in tumor research in recent years. The p53 protein has been shown to be a negative regulator of cell growth, an inhibitor of cellular transformation (for review see: Selter and Montenarh, 1994) and an inducer for programmed cell death (for review see: GoÈ tz and Montenarh, 1995). Whereas in the beginning the mutated form of this protein was considered to be the major cause leading to a loss of normal function other ways leading to loss of function are now emerging including secondary modi®cation, eg. by phosphorylation or interaction with other proteins . Observations which showed the existence of p53/MDM2 and p53/CK2 complexes are the basis to demonstrate also a possible CK2-MDM2 connection, especially since MDM2 harbors many CK2 consensus sequences. The data shown here con®rm the original speculations. CK2 phosphorylates MDM2 protein stoichiometrically and furthermore the phosphate incorporation can be increased in the presence of polylysine. Since MDM2 phosphorylation occurs also in the absence of polylysine it behaves like most CK2 substrates. In order to replace the`arti®cial' polybasic modulator by a more`natural' molecule we analysed the CK2-catalyzed MDM2 phosphorylation in the presence of a full length p53 or for convenience reasons a p53 peptide covering the carboxy terminal amino acids 264 ± 393. When an N-terminal fragment of p53 was used comprising amino acids 1 ± 287 (lacking the CK2b binding site) which is not phosphorylated by the CK2 holoenzyme no stimulation of CK2-catalyzed MDM2 was observed (results not shown). This result shows that the p53 carboxy terminus is responsible for the stimulatory eect of the CK2 holoenzyme-catalyzed MDM2 phosphorylation. Since the p53 peptide 264 ± 393 contains the CK2/p53 interaction site together with the polybasic amino acid stretch it is very likely that both are required for the observed stimulatory eect. This makes sense given the results obtained with the full length p53 molecule. The full length p53 molecule is simply too large and too heterogenous to act as a polycation solely, comparable to polylysine. Therefore, we postulate that the speci®c binding of p53 via its known CK2/p53 interaction domain, resulting in a CK2/p53 complex brings the polybasic carboxy terminus into the vicinity of a basic charge environment in CK2 mimicking the polylysine eect. This postulation is supported by observation from Guerra and Issinger (unpublished results) where it is shown that Ki-ras, which harbors a very distinct polybasic carboxy terminal stretch (amino acids 172 ± 182), does not stimulate MDM2 phosphorylation by the CK2 holoenzyme and indeed Ki-ras has never been shown to interact with CK2 supporting the notion that a speci®c interaction site with CK2 is a prerequisite for the action of a polybasic amino acid stretch.
Phosphorylation of p53 by CK2 has no in¯uence on MDM2 binding (Momand and Zambetti, 1996) . Olson et al. (1993) had shown that phosphorylated MDM2 is still found in a complex together with p53. Given the fact that MDM2 harbors an extraordinary number of possible phosphorylation sites we assume that it is not the overall phosphorylation one has to consider but that it is rather a detailed and speci®c phosphorylation site which is important for speci®c interaction with p53. Further investigations will be needed to explore the in vivo phosphorylation status of MDM2. This will then allow to throw light onto the role of CK2 in vivo phosphorylation of MDM2.
The C-terminus of p53 harbors the major nuclear localization signal (amino acids 310 ± 319) (Addison et al., 1990; Shaulsky et al., 1990 ) a non-speci®c DNA binding motif (amino acids 343 ± 390) (Foord et al., 1991) and the minimal transformation domain (Shaulian et al., 1992; Wang et al., 1993; Unger et al., 1993) , the region for the self oligomerization (StuÈ rzbecher et al., 1992) and for binding to various proteins (Appel et al., 1995; Wagner et al., 1994; Harris, 1996) . Loss of oligomerization of p53 correlates with loss of transformation activity of p53 (Slingerland et al., 1993) . p53 catalyzes the annealing of complementary DNA and RNA strands (Oberosler et al., 1993; Bakalkin et al., 1994) and this activity is inhibited by complex formation of p53 with CK2 (Filhol et al., 1996) . Thus, C-terminal sequences are implicated in protein ± protein interaction and these interactions lead to altered biological activities of the aected cellular proteins. p53 is phosphorylated by several protein kinases in vivo and in vitro (Meek and Eckhart, 1990; Meek et al., 1990; Herrmann et al., 1991; Milne et al., 1995; Milne et al., 1994 Milne et al., , 1996 LeesMiller et al., 1990 LeesMiller et al., , 1992 . It was previously shown that phosphorylation of p53 by CK2 at residue 392 is critical for the interaction of p53 with the b-subunit (Filhol et al., 1992) . However, we have shown that this is clearly not the case for the C-terminal fragment of p53 which shows no dierence in binding to phosphorylated or unphosphorylated p53 (Appel et al., 1995) . By replacing the potential serine-threonines of the CK2 consensus sequences in the p53 peptide through alanines we excluded the possibility that other eects apart from solely binding may be responsible for the stimulatory eect of the p53 peptide on MDM2 phosphorylation. Furthermore this peptide does not contain the MDM2 binding site (which is located in the amino terminal end) but shows several basic amino acid clusters (Soussi et al., 1990) , hence it could well surrogate the polylysine eect. As we could show this was indeed the case. Phosphate incorporation into MDM2 increased after the addition of p53 264 ± 393 , albeit not to the same extent as it was found with polylysine. Interestingly enough the p53 peptide was not capable of counteracting the negative regulatory eect of the CK2b-subunit when calmodulin was used as substrate for CK2 (results not shown). The inability of the p53 peptide to exert the polylysine eect when casein and the synthetic peptide were used instead of MDM2 as substrates may re¯ect a certain speci®city of the p53 peptide towards MDM2 phosphorylation. So either we have to postulate another, maybe weaker interaction or that casein and the synthetic peptide (RRRDDDSDDD) are so excellent ± albeit arti®cial substrates ± for CK2 that the observed eect of the p53 peptide with MDM2 as a substrate cannot be detected with casein and the synthetic peptide.
MDM2 is a phosphoprotein ) yet, we do not know whether CK2-catalyzed phosphorylation of MDM2 occurs also in vivo. However, the fact that there are several excellent CK2-speci®c phosphor-ylation sites in the MDM2 protein and that the phosphorylation by CK2 is stoichiometric supports the notion that CK2-catalyzed MDM2 phosphorylation might play a possible role in complex formation with p53. Another product of a p53 transactivated gene namely p21 WAF1/CIP1 is a poor substrate for protein kinase CK2. However, p21 WAF1/CIP1 down regulates phosphorylation of p53, casein and the autophosphorylation of the b-subunit of CK2. In the present study we demonstrate that p21 WAF1/CIP1 also downregulates the phosphorylation of MDM2 by CK2. The I 0.5 , ie. the concentration of p21 WAF1/CIP1 required for 50% inhibition of CK2 activity was determined to be 3610 76 M. Shim et al. (1996) had found that p21 WAF1/CIP1 acts as a non-enzymatic inhibitor of stress kinases. The observation that p21 WAF1/CIP1 also can act as an inhibitor of CK2 suggests it has several biochemical activities beside the ones originally described (El-Deiry et al., 1993; Harper et al., 1994) . Thus, regulation of the phosphorylation of MDM2 by p21
WAF1/CIP1 and CK2 may be part of the autoregulatory loop described for MDM2 (Picksley and Lane, 1993; Wu et al., 1993) .
p53 binds to the CK2b subunit in the CK2 holoenzyme complex (Appel et al., 1995) . We know that the CK2 phosphorylation site in p53 is not a common S/TXXD/E site and hence may be outcompeted in the presence of a better substrate, eg. MDM2. Therefore one could envisage a ternary enzyme/substrate complex between CK2/p53 and MDM2 where phosphorylation of MDM2 is enhanced by the cluster of basic amino acid residues of the p53 carboxyterminus. Amino acid residues 19 ± 102 from the MDM2 protein (of a total of 491) and amino acid residues 1 to 52 of the p53 protein (of a total of 393) are required to form p53-MDM2-complexes (CahillySnyder et al., 1987) , and therefore we could exclude an interaction between MDM2 and p53 which may have an in¯uence on the phosphorylation of MDM2 by CK2. In contrast in the case of p53/CK2, the interaction site in p53 is located in the carboxy terminal domain. Beside p53-MDM2-complexes Marechal et al. (1994) found a complex of 5S RNA-L5-MDM2-p53. Interestingly L5/CK2b interaction was found in the two-hybrid system screening a HeLa cDNA library, using CK2b as a bait which may support the notion of CK2 or CK2b subunit involvement in complex formation with p53/ MDM2/L5. Recent data from Momand and Zambetti (1996) strongly suggest that phosphorylation of p53 does not control complex formation with MDM2, however, nothing is known about the in¯uence of the phosphorylation of MDM2 on complex formation between MDM2 and p53. It was suggested that p53-MDM2 complex formation was controlled by a posttranslational event other than p53 phosphorylation. Hence, we suggest that the CK2 binding to p53 is the ®rst step, followed an enzyme substrate interaction with MDM2.
Another scenario could be that MDM2 becomes phosphorylated by CK2 and then can bind to p53. The presence of p53 would then enhance CK2-catalyzed phosphorylation thus stabilizing the MDM2/p53 complex. Further experiments in this direction will have to be done in order to explain the presence of free p53 and free MDM2 in various cell lines (Momand and Zambetti, 1996) . Since phosphorylation of p53 is no prerequisite for MDM2 binding, posttranslational modi®cation such as the observed MDM2 phosphorylation by CK2 or accessory proteins (eg. L5) may regulate p53-MDM2 complex formation.
Materials and methods
Puri®cation of protein kinase CK2 holoenzyme and CK2a
The a and b-subunits of protein kinase CK2 were expressed separately in a bacterial expression system (pT7-7/BL21 (DE3)). The bacterial pellets were mixed in a 1 : 1 ratio and then puri®ed according to Grankowski et al. (1991) with the following modi®cations. The S-I fraction, 1100 mg protein, was loaded onto a P11 phosphocellulose column (150 ml) and was equilibrated with buer A containing 300 mM NaCl (buer A, 25 mM Tris-HCl pH 8.5, 7 mM 2-mercaptoethanol, 0.2 mM phenylmethylsulfonyl¯uoride, PMSF). A linear gradient of 26500 ml in the range of 300 ± 1000 mM NaCl in buer A was applied. Active fractions (260 mg) eluting at approximately 700 mM NaCl, were collected, concentrated and equilibrated with 25 mM Tris-HCl pH 8.5, 1 M NaCl and loaded onto Superose 6 (Pharmacia). After gel ®ltration, the peak fractions were collected, concentrated and dialysed against 100 mM NaCl in buer A. The total yield of the CK2 preparations was 10 ± 15 mg from 20 g bacterial cells.
Phosphorylation assay with MDM2
The phosphorylation assay mix contained 1 mg MDM2 protein, 0.1 mU CK2 (1 U is the amount of protein kinase catalyzing the transfer of 1 mmole phosphate/min to the speci®c substrate) at 378C for 30 min in a ®nal volume of 12 ml in the presence of 25 mM Tris-HCl pH 8.5, 150 mM NaCl (in the case of CK2) or 20 mM NaCl, 5 mM MgCl 2 , 1 mM DTT, 50 mM [ 32 P]-g-ATP (speci®c activity 1000 ± 2000 c.p.m./pmol). For the evaluation of [ 32 P] incorporated, the reaction was stopped by adding SDS sample buer (0.14 M Tris-HCl, pH 6.8, 5.7% SDS, 12 mM DTT, 14% glycerol, 0.02% bromophenol blue) and aliquots were subjected to SDS ± PAGE. The dried gels were then exposed to autoradiography and measured in an Instant Imager apparatus (Packard;) alternatively the radioactive bands were excised and measured in a liquid scintillation counter.
Protein determination
Protein concentration was determined by the method of Bradford (1976) using bovine serum albumine as standard.
Plasmids and protein expression
The cDNA of p21 WAF1/CIP1 , the cDNAs of C-terminal fragments of human p53 and the cDNA of mouse mdm2 were cloned into the bacterial expression vector pQE-30 (Qiagen) (Appel et al., 1995) . All constructs possess a tag of six histidine residues for a one step puri®cation by metal chelate chromatography and the phosphorylation site for cAMP-dependent protein kinase.
Protein puri®cation of MDM2
Cells were harvested after a 3 h induction and resuspended in lysis buer (6 M guanidine hydrochloride, 50 mM NaH 2 PO 4 , pH 8.0) for the denaturing extraction of Histagged proteins. Cells were lysed for 1 h at room temperature or overnight at 48C with gentle stirring. The lysate was cleared by centrifugation (20 min 4000 g) and the supernatant was subjected to metal chelate chromatography on a Ni 2+ agarose column as described (Appel et al., 1995) . His-tagged proteins bound to the matrix were eluted by shifting the pH value of the lysis buer to pH 5.0. Eluted proteins were dialysed against 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.1% Tween 20.
